FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319171065> ?p ?o ?g. }

• W4319171065 endingPage "6" @default.
• W4319171065 startingPage "1" @default.
• W4319171065 abstract "Mucocutaneous lesions are the most frequent symptoms of Behçet’s disease (BD). Recently, new therapies are being used to treat refractory cases, but the effect of these treatments on mucocutaneous manifestations has been scarcely reported. Our objective was to describe the mucocutaneous response to the different therapies used to treat BD in routine clinical practice. We retrospectively reviewed the clinical records of all patients diagnosed with BD seen at our institution between January 2010 and January 2022. Patients with BD without mucocutaneous manifestations were excluded. We included 109 patients diagnosed with BD: 51 males (46.8%) and 58 females (53.2%). The mean age at diagnosis was 31.58 years (standard deviation (SD) 12.110) and the mean time of disease evolution was 14.94 years (SD 11.094). Oral ulcers were the most frequent symptom present in 100% of patients, followed by genital ulcers (GU) in 76.1% of patients. Twenty-four patients (22%) had severe mucocutaneous symptoms (>12 lesions/year) before treatment. We found that among patients with GU there was a higher prevalence of episodes of posterior uveitis and venous thrombosis ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M1> <mi>p</mi> <mo>=</mo> <mn>0.011</mn> </math> and <math xmlns=http://www.w3.org/1998/Math/MathML id=M2> <mi>p</mi> <mo>=</mo> <mn>0.045</mn> </math> , respectively). In our series, we observed a lower complete cutaneous response to colchicine in patients with GU, pathergy or severe mucocutaneous symptoms ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M3> <mi>p</mi> <mo><</mo> <mn>0.05</mn> </math> ). Regarding the choice of a TNF-α inhibitor, we observed a lower prevalence of complete cutaneous response to adalimumab among patients with GU (53.3% complete response in patients with GU vs. 100% in patients without GU, <math xmlns=http://www.w3.org/1998/Math/MathML id=M4> <mi>p</mi> <mo>=</mo> <mn>0.022</mn> </math> ), whereas no differences were found between clinical characteristics in the response to infliximab." @default.
• W4319171065 created "2023-02-04" @default.
• W4319171065 creator A5008485597 @default.
• W4319171065 creator A5026555069 @default.
• W4319171065 creator A5030856020 @default.
• W4319171065 creator A5033725158 @default.
• W4319171065 creator A5082254348 @default.
• W4319171065 date "2023-02-04" @default.
• W4319171065 modified "2023-10-06" @default.
• W4319171065 title "Mucocutaneous Response to New Therapeutic Strategies in Behçet’s Disease: A Retrospective Cohort Study" @default.
• W4319171065 cites W1972240373 @default.
• W4319171065 cites W2796372149 @default.
• W4319171065 cites W2804866854 @default.
• W4319171065 cites W2994209913 @default.
• W4319171065 cites W2999001344 @default.
• W4319171065 cites W3111665062 @default.
• W4319171065 cites W3128708152 @default.
• W4319171065 cites W3164690212 @default.
• W4319171065 cites W4245048399 @default.
• W4319171065 cites W998070158 @default.
• W4319171065 doi "https://doi.org/10.1155/2023/1415353" @default.
• W4319171065 hasPublicationYear "2023" @default.
• W4319171065 type Work @default.
• W4319171065 citedByCount "0" @default.
• W4319171065 crossrefType "journal-article" @default.
• W4319171065 hasAuthorship W4319171065A5008485597 @default.
• W4319171065 hasAuthorship W4319171065A5026555069 @default.
• W4319171065 hasAuthorship W4319171065A5030856020 @default.
• W4319171065 hasAuthorship W4319171065A5033725158 @default.
• W4319171065 hasAuthorship W4319171065A5082254348 @default.
• W4319171065 hasBestOaLocation W43191710651 @default.
• W4319171065 hasConcept C121332964 @default.
• W4319171065 hasConcept C126322002 @default.
• W4319171065 hasConcept C141071460 @default.
• W4319171065 hasConcept C142424586 @default.
• W4319171065 hasConcept C156662089 @default.
• W4319171065 hasConcept C16005928 @default.
• W4319171065 hasConcept C167135981 @default.
• W4319171065 hasConcept C2776554866 @default.
• W4319171065 hasConcept C2779134260 @default.
• W4319171065 hasConcept C2781428731 @default.
• W4319171065 hasConcept C71924100 @default.
• W4319171065 hasConcept C87355193 @default.
• W4319171065 hasConceptScore W4319171065C121332964 @default.
• W4319171065 hasConceptScore W4319171065C126322002 @default.
• W4319171065 hasConceptScore W4319171065C141071460 @default.
• W4319171065 hasConceptScore W4319171065C142424586 @default.
• W4319171065 hasConceptScore W4319171065C156662089 @default.
• W4319171065 hasConceptScore W4319171065C16005928 @default.
• W4319171065 hasConceptScore W4319171065C167135981 @default.
• W4319171065 hasConceptScore W4319171065C2776554866 @default.
• W4319171065 hasConceptScore W4319171065C2779134260 @default.
• W4319171065 hasConceptScore W4319171065C2781428731 @default.
• W4319171065 hasConceptScore W4319171065C71924100 @default.
• W4319171065 hasConceptScore W4319171065C87355193 @default.
• W4319171065 hasLocation W43191710651 @default.
• W4319171065 hasOpenAccess W4319171065 @default.
• W4319171065 hasPrimaryLocation W43191710651 @default.
• W4319171065 hasRelatedWork W11080822 @default.
• W4319171065 hasRelatedWork W199624821 @default.
• W4319171065 hasRelatedWork W2012749901 @default.
• W4319171065 hasRelatedWork W2079028206 @default.
• W4319171065 hasRelatedWork W2111836627 @default.
• W4319171065 hasRelatedWork W2116353845 @default.
• W4319171065 hasRelatedWork W2417108066 @default.
• W4319171065 hasRelatedWork W2462615396 @default.
• W4319171065 hasRelatedWork W2613228477 @default.
• W4319171065 hasRelatedWork W3128708152 @default.
• W4319171065 hasVolume "2023" @default.
• W4319171065 isParatext "false" @default.
• W4319171065 isRetracted "false" @default.
• W4319171065 workType "article" @default.